• Profile
Close

Patient-reported outcomes and inflammatory biomarkers in patients with locally advanced/metastatic urothelial carcinoma treated with durvalumab in phase 1/2 dose-escalation Study 1108

Cancer Oct 13, 2019

O'Donnell PH, Arkenau HT, Sridhar SS, et al. - Given that a meaningful clinical activity of durvalumab in patients with metastatic urothelial carcinoma (mUC) has been reported in Study 1108, researchers undertook this inquiry to explore patient-reported outcomes (PROs) from Study 1108 as well as their link with inflammatory biomarkers. Using the Functional Assessment of Cancer Therapy–Bladder and the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30, the evaluation of disease-related symptoms, functioning, and health-related quality of life (HRQOL) was done. Findings revealed improvements in disease-associated symptoms, functioning, and HRQOL in correlation with durvalumab treatment in patients with mUC. A possible contribution of improvements in systemic inflammation to PRO improvements was suggested.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay